All In Biotech

NDA 022117 · Abbvie

Saphris

Asenapine Maleate · Sublingual

Novel

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 13, 2009

Approved uses

7

Original approval plus efficacy supplements

Registered trials

51

35 Phase 3, 0 recruiting

FAERS reports

7,825

3,466 serious, 279 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SAPHRIS ® (asenapine) is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1, 5.2 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SAPHRIS is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 5.2 )

What it is approved for

From the label in effect Jan 31, 2025.

1 INDICATIONS AN D USAGE SAPHRIS is indicated for: Schizophrenia in adults [see Clinical Studies ( 14.1 )] Bipolar I disorder [see Clinical Studies ( 14.2 )] • Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age • Adjunctive treatment to lithium or valproate in adults • Maintenance monotherapy treatment in adults SAPHRIS is an atypical antipsychotic indicated for ( 1 ): Schizophrenia in adults Bipolar I disorder ○ Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age ○ Adjunctive treatment to lithium or valproate in adults ○ Maintenance monotherapy treatment in adults

Mechanism: The mechanism of action of asenapine, in schizophrenia and bipolar I disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SAPHRIS · ASENAPINE MALEATE EQ 5MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB
  • SAPHRIS · ASENAPINE MALEATE EQ 10MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB
  • SAPHRIS · ASENAPINE MALEATE EQ 2.5MG BASE · TABLET, SUBLINGUAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Asenapine" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective806
  • sedation667
  • suicide attempt651
  • inappropriate schedule of drug administration557
  • weight increased537
  • dyskinesia520
  • dystonia496
  • blood glucose increased477
  • sexual dysfunction427
  • anosognosia423
  • blood prolactin abnormal413
  • metabolic disorder413

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200917
20101,716
20111,017
20121,003
20131,397
2014197
2015152
2016279
2017215
2018206
2019306
2020241
2021265
2022288
2023232
2024111
2025109
202674

Recalls

1 FDA enforcement reports for this application.

  • May 18, 2017 · Class II · Terminated

    Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Saphris (Asenapine Maleate)

2024 spending

$7.2M

Beneficiaries

933

6,204 claims

Per beneficiary

$7,683

$19.61 per unit

View as table
YearSpending
2020$107,720,607
2021$39,919,860
2022$12,288,835
2023$9,012,113
2024$7,167,784

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 119 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.